glp 1 gip dual agonist weight loss GIPR/GLP-1R therapies for diabetes and loss—chemistry, physiology, and clinical applications GLP-1/GIP dual agonist confers 'robust'

Rapid weight loss, however, can also cause bone density loss

10.1517/17425255.2012.686603 166 ScheenA

The Top 3 Recommended Injection Sites Medical guidelines identify three primary areas that are safe and effective for subcutaneous injections

The brain pathway may be more significant than the endocrine route for the physiological effects of GLP-1, especially regarding insulin release, but the endocrine route becomes more pronounced with bigger meals and more L-cell activation (Deacon 2019)

Retatrutide also remains investigational, with ClinicalTrials.gov listing active or recently updated Phase 3 research records as of May 2026